The Cigna Group (CI) investor relations material

Strategy and portfolio

• Lead to One aligns 60,000+ colleagues around personalization at scale, using data, clinical expertise, technology and AI to improve affordability and customer experience across the care continuum.

• Portfolio shifted from a health-plan focus to Specialty and Care Services, Pharmacy Benefit Services and employer-focused Cigna Healthcare; non-core businesses were divested, including the Individual and Family Plan exit effective January 2027.

• Complex care represents 8% of patients but 55% of healthcare spending; it accounts for all Specialty and Care activity, ~55% of Cigna Healthcare spending impacted and ~70% of Pharmacy Benefit Services spending impacted.

• Specialty and Care reached 37% of enterprise adjusted earnings in 2026, up 7 percentage points since 2024; the Select customer base grew 12%.

• Specialty and Care is expected to be the fastest-growing platform through 2030, with income growth expected across all three platforms.

Financial outlook and capital allocation

• Reaffirmed 2026 guidance: at least $30.45 adjusted EPS, $6.9B pre-tax adjusted income from operations for Evernorth Health Services and $4.55B for Cigna Healthcare.

• 2026-2030 outlook: 6%-9% average annual operating earnings growth plus 4%-5% from capital deployment, supporting 10%-14% adjusted EPS CAGR; at least 10% EPS growth expected in 2027.

• 2030 adjusted EPS floor is $45, based on the low end of growth ranges and achievable with Pharmacy Benefit Services flat through 2030.

• Segment outlooks through 2030: Evernorth 5%-8%; Specialty and Care 8%-12% (7%-9% core, 1%-3% differentiated growth); Pharmacy Benefit Services flat to 4%; Cigna Healthcare 6%-9%.

• 2026-2030 operating cash flow target is ~$50B; allocate 20%-25% to business investment, ~20% to dividends and 55%-60% to repurchases, debt repayment and M&A; target ~40% debt-to-capital by end-2026.

Specialty and care services

• Specialty is a ~$480B market growing at a high-single-digit rate; new products are expected to add ~$100B in sales by 2030, while ~$100B of annual spend faces new competition.

• Accredo serves >1M patients and fills >8M specialty prescriptions annually, with access to >330 limited-distribution drugs, including >30 exclusive products, and 15 disease-focused Therapeutic Resource Centers.

• Four clean rooms are operating and a fifth is being built; CuraScript distribution grew ~20% annually for five years and serves >12,000 providers.

• Specialty and Care targets 8%-12% annual earnings growth and >40% of enterprise earnings by 2030, with ~$20B in new distribution revenue planned; Pharmacy Forward uses AI to halve time to therapy.

• Planned expansion includes Evernorth Wholesale Distribution and a pharmacy network expected to grow from ~2M to ~6M enrolled lives by Jan. 1.